TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00632762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mantadix
Description: dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).
Study: NCT00555373

Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: 1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~2. Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours).
Study: NCT03795610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549
Description: 40mg by mouth (PO) every day (QD) for at least 14 days
Study: NCT00632762

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mantadix
Description: dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).
Study: NCT04525300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
Study: NCT01410552

Intervention type: DEVICE
Group type: OTHER
Intervention: PARADYM DR model 8550; PARADYM CRT model 8750; PARADYM RF DR model 9550; PARADYM RF CRT model 9750; PARADYM RF CRT SonR model 9770
Description: PARADYM ICD and CRT-d with PARAD+ algorithm available
Study: NCT00198796

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H10407
Description: The primary objective of the proposed clinical investigation is to validate a dose for ETEC H10407 that will cause diarrhea in 50% or more of subjects without causing high output diarrhea
Study: NCT02782429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT02332317

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Palliative rehabilitation
Description: 12-week individually customized, specialized palliative rehabilitation program
Study: NCT02213900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: 0.5mg IV Push immediately after surgery and Q8H following for a total of 4 days
Study: NCT03981302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family nursing conversations
Description: The intervention is based on the concept family systems nursing developed by Wright \& Maureen. Family nursing aims to change restricting beliefs and alleviate illness suffering. The Illness Beliefs model and Calgarymodels are essential components. The illness beliefs model illuminates the family's different beliefs about their problems. The Calgary models consist of the Calgary family assessment model and the Calgary intervention model and aim to support change and help the family to find new ways to handle the illness. The use of the components cannot be standardised but must be tailored to match the needs of the specific family. The family nursing conversations in this intervention will last 1,5 hour. Every family will be offered three family nursing conversations with roughly three weeks interval. If the family after three conversations express a need for follow-up, they will be offered the fourth conversation.
Study: NCT03762850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irbesartan
Description: Target dose of 300 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Target dose of 10 mg daily
Study: NCT02789228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor associated antigen lymphocytes (TAA-CTL)
Description: This protocol is designed as a phase I dose-escalation study. In each treatment group (A and B), patients will be enrolled to one of the following TAA-T dose levels:~Dose Level One: 1 x 107 cells/m2 Dose Level Two: 2 x 107 cells/m2 Dose Level Three: 4 x 107 cells/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor associated antigen lymphocytes (TAA-CTL)
Description: This protocol is designed as a phase I dose-escalation study. In each treatment group (A and B), patients will be enrolled to one of the following TAA-T dose levels:~Dose Level One: 1 x 107 cells/m2 Dose Level Two: 2 x 107 cells/m2 Dose Level Three: 4 x 107 cells/m2
Study: NCT01266707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: antiangiogenic paptide vaccine
Description: for drugs include administration time frame
Study: NCT04452812

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Convalescent plasma
Description: Best available treatment + convalescent plasma~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.~Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Best available treatment + convalescent plasma~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.~Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval.
Study: NCT03041376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking intervention
Description: The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
Study: NCT04455360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol
Description: EMDR is a form of psychotherapy treatment whereby the client verbally relates a narrative of a traumatic episode or emotionally disturbing material in brief sequential doses while simultaneously focusing on an external stimulus. The EMDR Recent-Traumatic Events protocol (R-TEP) aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR R-TEP should be delivered within 3-months of the onset of a traumatic event.
Study: NCT03559985

Intervention type: DRUG
Group type: OTHER
Intervention: paracetamol
Description: Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.

Intervention type: DRUG
Group type: OTHER
Intervention: paracetamol
Description: Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo comparator
Description: Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo comparator
Description: Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.
Study: NCT02213900

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02945202

Intervention type: DEVICE
Group type: OTHER
Intervention: Biometry
Description: All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery

Intervention type: DEVICE
Group type: OTHER
Intervention: Refraction
Description: All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery

Intervention type: DEVICE
Group type: OTHER
Intervention: Corneal Topography
Description: All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
Study: NCT00056290

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VEGF
Description: 3 sets of injections, at 2 week intervals

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VEGF
Description: 3 sets of injections, at 2 week intervals
Study: NCT03280732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound
Description: A Mindray-DC-T6 ultrasound machine equipped with a linear probe with frequencies ranging from 7.5 to 12 MHz will be use. LUS examination will consist of both longitudinal and transversal sections according to the methodology described by Copetti and colleagues.
Study: NCT03177135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmnioSense
Description: A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis.
Study: NCT02235259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG-104
Description: Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG-104
Description: Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG-104
Description: Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03544476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone TB treatment support app plus usual care
Description: The behavioral intervention is delivered through a mobile phone TB support app. The functions allow the participant to: self-report daily administration of their TB medication, self-report side effects if applicable, review educational material on TB disease and its treatment, complete a treatment adherence monitoring test (urine drug metabolite test), take notes, and review their treatment progress/report. The drug metabolite test will require that the participant place a small amount of urine on the end of the paper strip, wait for results, and take a picture of the paper using the app. The purpose of this test is to confirm that medication was correctly taken within the past 24 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
Study: NCT01108289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxytocin in Uniject
Description: 10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
Study: NCT03550651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Licorice
Description: Licorice, since years is known for its anti-inflammatory, antimicrobial, antiviral, antiprotozoal, antioxidative, hepatoprotective, cardioprotective, immunomodulatory and antitumour activity. Licorice can be beneficial for oral health. Glycyrrhizin, the sweet component of licorice root has antiplaque property. Pterocarpenes isolated from G. uralensis root extract exerts an antibacterial activity against Streptococcus mutans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic salt solution
Description: The antiseptic and bactericidal qualities of salt help in removing plaque which is a cause of gingivitis and caries. Warming water with a pinch of table salt can reduce or even be an alternative to anti-inflammatory drugs intra-orally. Its high osmolality reduces inflammation and can be microbicidal. Moreover, efficacy of luke warm hypertonic salt solution has shown antimicrobial, anti-inflammatory and immunomodulatory properties.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Essential oil
Description: Essential oils have a wide application in folk medicine, food flavoring and preservation as well as in fragrance industries. The antimicrobial properties of essential oils have been known for many centuries. In recent years, a large number of essential oils and their constituents have been investigated for their antimicrobial properties against some bacteria and fungi. Essential oils have the potential to be used as therapeutic agents for chronic gingivitis and periodontitis conditions that have both bacterial and inflammatory components.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Chlorhexidine is a symmetrical bisbiguanide synthetic antiseptic. It is available in three forms, digluconate, acetate and hydrochloride salts. Which have broad spectrum antimicrobial activity; it is effective against both Gram-positive and Gram-negative bacteria including aerobes and anaerobes, yeasts, fungi and lipid enveloped viruses. Chlorhexidine is considered to be the most effective plaque inhibitor against which other antiplaque agents are measured.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: Distilled water is commonly placebo in various research projects and it is also useful in as placebo treatment.
Study: NCT02973607

Intervention type: PROCEDURE
Intervention: Nephrectomy
Description: This is observational in design.
Study: NCT03416374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib intravenous infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets
Study: NCT03083158

Intervention type: DRUG
Group type: OTHER
Intervention: Hepatitis B vaccine
Description: 1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection

Intervention type: DRUG
Group type: OTHER
Intervention: Hepatitis B vaccine
Description: 1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection
Study: NCT02818153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self questionnaire for allergic rhinitis control
Study: NCT01937767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study: NCT03639571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg TEPI Medicated Plaster
Description: Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TEPI Plaster
Description: Placebo TEPI Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
Study: NCT04533958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYPNO VR® device
Description: The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.~Before each Docetaxel infusion, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the chemotherapy program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.~After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the return and exit hypnosis phase under the supervision of the nursing staff.
Study: NCT03463031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSP 301 NS
Description: 1 spray in each nostril twice daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSP 301 Placebo NS
Description: 1 spray in each nostril twice daily for 14 days
Study: NCT04348890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 4% suspension for oral dosing
Description: vamorolone 6 mg/kg/day orally once daily for 8 weeks.
Study: NCT01361854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polysomnography
Description: home-based polysomnography with hook-up performed ar at home or in the hospital
Study: NCT04499599

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dinner
Description: Study subjects will consume a standardized ready-to-eat meal as dinner.
Study: NCT01937767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Study: NCT04499599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dinner
Description: Study subjects will consume a standardized ready-to-eat meal as dinner.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dinner
Description: Study subjects will consume a standardized ready-to-eat meal as dinner.
Study: NCT03738241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: 0.006M PBS diluent for Influenza Virus Vaccine.
Study: NCT01937767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study: NCT03738241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: 0.006M PBS diluent for Influenza Virus Vaccine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: 0.006M PBS diluent for Influenza Virus Vaccine.
Study: NCT04499599

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fasting
Description: Subjects in all groups will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1 and then fast overnight for approximately 15 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Subjects in all groups will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1 and then fast overnight for approximately 15 hours.
Study: NCT01937767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Study: NCT04499599

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fasting
Description: Subjects in all groups will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1 and then fast overnight for approximately 15 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Study food
Description: Study subjects will either continue to fast for 6 hours (Fast Group), consume either a breakfast (Breakfast Group) or a Fast Bar (Fast Bar Group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study food
Description: Study subjects will either continue to fast for 6 hours (Fast Group), consume either a breakfast (Breakfast Group) or a Fast Bar (Fast Bar Group).
Study: NCT01168960

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy for alcohol dependence
Description: 12-session behavioral treatment that incorporates behavioral skills training targeting high-risk drinking behavior.
Study: NCT01373307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LHA-delivered energy balance classes/activities
Description: 4-6 sessions delivered by local LHA to age-appropriate groups (i.e., children/adolescents and adults), based on We Can! And Media Smart Youth curricula.
Study: NCT04222647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WO533
Description: Intravaginal application